Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,693,474 papers from all fields of science
Search
Sign In
Create Free Account
STARD13 gene
Known as:
StAR related lipid transfer domain containing 13
, STARD13
, ARHGAP37
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
STARD10 gene
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
StarD13: a potential star target for tumor therapeutics
Leila Jaafar
,
Zeinab Chamseddine
,
M. El-Sibai
Human Cell
2020
Corpus ID: 215531997
StarD13 is a tumor suppressor and a GTPase activating protein (GAP) for Rho GTPases. Thus, StarD13 regulates cell survival…
Expand
2019
2019
Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma
Dominika Wołosz
,
Agnieszka Walczak
,
+4 authors
B. Gornicka
European Journal of Histochemistry
2019
Corpus ID: 73484092
Deleted in Liver Cancer (DLC) proteins belong to the family of RhoGAPs and are believed to operate as negative regulators of the…
Expand
2018
2018
DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway
Zhengxu Yang
,
Hanrui Chen
,
Man Shu
,
Yunjian Zhang
,
L. Xue
,
Yuan Lin
Oncology Letters
2018
Corpus ID: 59602426
Deleted in liver cancer 2 (DLC2) is a tumor suppressor, associated with various types of cancer. The aim of the present study was…
Expand
2014
2014
Effect of StarD13 on colorectal cancer proliferation, motility and invasion.
Anita I. Nasrallah
,
Bechara Saykali
,
Saleh Al Dimassi
,
N. Khoury
,
Samer J Hanna
,
M. El-Sibai
Oncology Report
2014
Corpus ID: 2364746
Colon cancer is a cancer of the epithelial cells lining the colon. It is mainly divided into different stages according to the…
Expand
Review
2013
Review
2013
The STAR of the DLC family
Sally El-Sitt
,
M. El-Sibai
Journal of Receptor and Signal Transduction…
2013
Corpus ID: 26208347
Abstract RhoGTPases are defined as a family of 20 small G proteins playing important roles in almost every cellular process…
Expand
2013
2013
RhoGAP control of pancreas development
Tomasz Zygmunt
,
F. Spagnoli
Small GTPases
2013
Corpus ID: 207520533
Recent evidences suggested that growth and differentiation of pancreatic cell lineages, including the insulin-producing β-cells…
Expand
2012
2012
Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters.
K. Gao
,
Xiaorong Li
,
G. Hu
,
Kaiyan Yang
,
Buning Tian
,
Yi Zhang
Oncology Letters
2012
Corpus ID: 22205387
Deleted in liver cancer 2 (DLC2) has been identified as a tumor suppressor gene. DLC2 is closely related to deleted in liver…
Expand
2010
2010
Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone—An array comparative genomic hybridization study
T. Niini
,
J. López-Guerrero
,
+8 authors
S. Knuutila
Genes, Chromosomes and Cancer
2010
Corpus ID: 30783642
Very little is known about the genetics of fibrosarcoma (FS) of bone. We applied array comparative genomic hybridization (CGH) to…
Expand
2008
2008
Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma
L. Xiaorong
,
Wu Wei
,
Qian Liyuan
,
Yong Kaiyan
BMC Cancer
2008
Corpus ID: 2364399
BackgroundDLC2, a unique RhoGAP, has been recently identified as a tumor suppressor gene in hepatocellular carcinoma (HCC…
Expand
Highly Cited
2006
Highly Cited
2006
Alternatively spliced exon B of myosin Va is essential for binding the tail-associated light chain shared by dynein.
Zsuzsanna Hódi
,
A. Németh
,
+5 authors
L. Nyitray
Biochemistry
2006
Corpus ID: 39465715
A 10 kDa dynein light chain (DLC), previously identified as a tail light chain of myosin Va, may function as a cargo-binding and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE